The Fed's Ambivalence: What Investors Can Expect from Its Dovish Shift
While the Federal Reserve has kept interest rates unchanged, recently released economic data such as PCE, CPI, and the unemployment rate suggest that inflation is trending in the right direction, leading the market to believe that a cycle of decreasing interest rates will begin soon. However, the debate continues; it's not about "whether or not," but rather "when and how" rate cuts will occur.
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company's impressive second
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Tec
Schrodinger Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 48.83% Leerink Partners → $29 Initiates Coverage On → Outperform 05/02/2024 89.89% Citigroup $3
Arcturus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 157.62% HC Wainwright & Co. $60 → $60 Reiterates Buy → Buy 05/10/2024 269.26% Canaccord Genuity
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains momentum.
Arcturus to File IND for Phase 2 Study for Cystic Fibrosis Candidate
Arcturus Therapeutics Provides Mid-Year Updates For ARCT-810, Ornithine Transcarbamylase Deficiency And Cystic Fibrosis Programs
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this yearARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more sev
Will Trump's Debate Advantage Give Biotech and Healthcare Stocks a Lift?
As the dust settles on the latest presidential debate, market analysts are scrutinizing the implications of a potential shift in the political landscape.
Twist Bioscience Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 24.64% Barclays $45 → $60 Maintains Overweight 06/13/2024 35.02% TD Cowen $55 → $65 Maintains B
Expert Outlook: Nurix Therapeutics Through The Eyes Of 14 Analysts
In the last three months, 14 analysts have published ratings on Nurix Therapeutics (NASDAQ:NRIX), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their rece
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 23.99% RBC Capital $23 → $26 Maintains Outperform 06/18/2024 23.99% HC Wainwright & Co. $19 → $
Cathie Wood's Top and Bottom Performing ARKK Holdings of H1
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.
Intellia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 213.71% Canaccord Genuity $73 → $73 Maintains Buy 06/24/2024 179.33% Cantor Fitzgerald $65 → $6
Why Recursion Pharmaceuticals Stock Is Tumbling Thursday
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Thursday after the company announced a proposed offering of its common stock.What Happened: Recursion announced that it intends to
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
6 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates th
Market-Moving News for June 27th
CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Proposal To Acquire Its China Business For Aggregate Purchase Price Of $40MME
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday.Shares of Levi Strauss & Co. (NYSE:LEVI) fell sharply in today's pre-market trading after the compan
Ionis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 10.46% Stifel $50 → $53 Maintains Hold 06/14/2024 — Bernstein Upgrades Underperform → Market P